Skip to main content

Table 1 Patients’ baseline characteristics (N = 20)

From: Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants including edoxaban

Age

66 ± 10.5 years

Female sex

8 (40%)

Edoxaban dose

60 mg daily: 15 (75%)

30 mg daily: 5 (25%)

Body weight

80.5 ± 20.1 kg

Body Mass Index (BMI)

27.0 ± 5.9 kg/m2

Glomerular filtration rate (Cockcroft-Gault)

83 ± 26 mL/min/1.73m2

Risk factors

 Arterial hypertension

16 (80%)

 Hyperlipidemia

7 (35%)

 Diabetes mellitus

1 (5%)

 History of stroke

20 (100%)

 Congestive heart failure

2 (10%)

 Coronary heart disease

7 (35%)

 History of myocardial infarction

5 (25%)

 Smoking

4 (20%)

Indication for edoxaban therapy

 Atrial fibrillation

12 (60%)

 Stroke associated with patent foramen ovale

6 (30%)

 Embolic stroke of undetermined source

2 (10%)

Concomitant antiplatelet therapy

4 (20%)

  1. Continuous variables are displayed as mean ± standard deviation. Nominal variables are displayed as absolute quantity (percentage)